Alpine Immune Sciences Inc
F:34LA
Intrinsic Value
The intrinsic value of one 34LA stock under the Base Case scenario is 8.96 EUR. Compared to the current market price of 59 EUR, Alpine Immune Sciences Inc is Overvalued by 85%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Alpine Immune Sciences Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Alpine Immune Sciences Inc
Balance Sheet Decomposition
Alpine Immune Sciences Inc
Current Assets | 308.3m |
Cash & Short-Term Investments | 305.7m |
Receivables | 543k |
Other Current Assets | 2m |
Non-Current Assets | 65.4m |
Long-Term Investments | 56.5m |
PP&E | 8.7m |
Other Non-Current Assets | 269k |
Free Cash Flow Analysis
Alpine Immune Sciences Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Alpine Immune Sciences Inc
Revenue
|
56.5m
USD
|
Operating Expenses
|
-107.9m
USD
|
Operating Income
|
-51.4m
USD
|
Other Expenses
|
14.5m
USD
|
Net Income
|
-36.8m
USD
|
34LA Profitability Score
Profitability Due Diligence
Alpine Immune Sciences Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Alpine Immune Sciences Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
34LA Solvency Score
Solvency Due Diligence
Alpine Immune Sciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Alpine Immune Sciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
34LA Price Targets Summary
Alpine Immune Sciences Inc
Dividends
Current shareholder yield for 34LA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one 34LA stock under the Base Case scenario is 8.96 EUR.
Compared to the current market price of 59 EUR, Alpine Immune Sciences Inc is Overvalued by 85%.